| 1.46 0.015 (1.05%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.83 | 1-year : | 1.98 |
| Resists | First : | 1.57 | Second : | 1.7 |
| Pivot price | 1.49  |
|||
| Supports | First : | 1.37 | Second : | 1.13 |
| MAs | MA(5) : | 1.44 |
MA(20) : | 1.5 |
| MA(100) : | 1.68 |
MA(250) : | 2.46 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 24.2 |
D(3) : | 19.9 |
| RSI | RSI(14): 41.7 |
|||
| 52-week | High : | 5.01 | Low : | 1.37 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ APRE ] has closed above bottom band by 32.9%. Bollinger Bands are 33.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.53 - 1.54 | 1.54 - 1.54 |
| Low: | 1.39 - 1.4 | 1.4 - 1.4 |
| Close: | 1.45 - 1.46 | 1.46 - 1.47 |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Thu, 28 Aug 2025
Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference - The Manila Times
Thu, 28 Aug 2025
Clinical-Stage Cancer Drug Developer Aprea Therapeutics to Present Latest Updates at Major Investment Conference - Stock Titan
Tue, 12 Aug 2025
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update - The Manila Times
Tue, 12 Aug 2025
Breakthrough: Aprea's Novel Cancer Drugs Show Disease Control in 10 Patients Across Two Clinical Trials - Stock Titan
Tue, 12 Aug 2025
Aprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingView
Tue, 12 Aug 2025
Aprea Therapeutics Reports Promising Q2 2025 Results - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 4.64e+006 (%) |
| Held by Institutions | 11.3 (%) |
| Shares Short | 56 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.477e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 868.2 % |
| Return on Equity (ttm) | -39.2 % |
| Qtrly Rev. Growth | 841010 % |
| Gross Profit (p.s.) | -50 |
| Sales Per Share | -42.75 |
| EBITDA (p.s.) | -5.5443e+006 |
| Qtrly Earnings Growth | -2.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 0.99 |
| Dividend | 0 |
| Forward Dividend | 84500 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|